Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid

Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid

Duchenne muscular dystrophy (DMD) is a fatal muscle-wasting disease arising from mutations in the dystrophin gene. Upregulation of utrophin to compensate for the missing dystrophin offers a potential therapy independent of patient genotype. The first-in-class utrophin modulator ezutromid/SMT C1100 w...

Full description

Bibliographic Details
Main Authors:	Wilkinson, IVL, Perkins, KJ, Dugdale, H, Moir, L, Vuorinen, A, Chatzopoulou, M, Squire, SE, Monecke, S, Lomow, A, Geese, M, Charles, PD, Burch, P, Tinsley, JM, Wynne, GM, Davies, SG, Wilson, FX, Rastinejad, F, Mohammed, S, Davies, KE, Russell, AJ
Format:	Journal article
Language:	English
Published:	Wiley 2019

Similar Items

Isolation, structural identification, synthesis, and pharmacological profiling of 1,2-trans-dihydro-1,2-diol metabolites of the utrophin modulator ezutromid
by: Chatzopoulou, M, et al.
Published: (2019)

Utrophin in the therapy of Duchenne Muscular Dystrophy
by: Potter, A, et al.
Published: (2006)

Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
by: Wilkinson, I
Published: (2019)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
by: Kennedy, T, et al.
Published: (2017)

Non-toxic ubiquitous overexpression of utrophin in the mdx mouse.
by: Fisher, R, et al.
Published: (2000)

Second-generation compound for the modulation of utrophin in the therapy of DMD
by: Guiraud, S, et al.
Published: (2015)

From diagnosis to therapy in Duchenne muscular dystrophy
by: Babbs, A, et al.
Published: (2020)

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.
by: Fisher, R, et al.
Published: (2001)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
by: Fairclough, R, et al.
Published: (2014)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
by: Perkins, K, et al.
Published: (2002)

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
by: Wakefield, P, et al.
Published: (2000)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
by: Fairclough, R, et al.
Published: (2012)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
by: Fairclough, R, et al.
Published: (2008)

Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
by: Guiraud, S, et al.
Published: (2018)

A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet
by: Muntoni, F, et al.
Published: (2019)

Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.
by: Squire, S, et al.
Published: (2002)

Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
by: Sang, E, et al.
Published: (2000)

The utrophin and dystrophin genes share similarities in genomic structure.
by: Pearce, M, et al.
Published: (1993)

Towards the elucidation of the mechanism of action of small molecule upregulators of utrophin using chemical proteomics
by: Vuorinen, A
Published: (2017)

Regulation of utrophin in transgenic mice.
by: Davies, K
Published: (2005)

Utrophin upregulation in DMD therapy: current status and new tools for the future
by: Fairclough, R, et al.
Published: (2011)

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.
by: Sewry, C, et al.
Published: (2005)

Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice
by: Kennedy, T, et al.
Published: (2018)

Understanding the endothelial function of utrophin.
by: Ehmsen, J, et al.
Published: (2002)

Identification of serum protein biomarkers for utrophin based DMD therapy.
by: Guiraud, S, et al.
Published: (2017)

Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation
by: Fairclough, R, et al.
Published: (2010)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
by: Perkins, K, et al.
Published: (2018)

The artificial zinc finger coding gene 'Jazz' binds the utrophin promoter and activates transcription.
by: Corbi, N, et al.
Published: (2000)

Confirmation by immunogold labeling that utrophin is localised to the normal position of dystrophin in dystrophin-negative transgenic mouse muscle
by: Cullen, M, et al.
Published: (2001)

Characterisation of utrophin modulator SMT C1100 as a non-competitive inhibitor of firefly luciferase
by: Wilkinson, I, et al.
Published: (2019)

Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure.
by: Rafael, J, et al.
Published: (2000)

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
by: Tinsley, J, et al.
Published: (2015)

Ets, Ap-1 and GATA factor families regulate the utrophin B promoter: potential regulatory mechanisms for endothelial-specific expression.
by: Perkins, K, et al.
Published: (2003)

Utrophin upregulation in Duchenne muscular dystrophy.
by: Hirst, R, et al.
Published: (2005)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
by: Perkins, K, et al.
Published: (2000)

The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
by: Perkins, K, et al.
Published: (2001)

Novel 5 '-utrophin isoforms exhibit species-specific transcriptional profiles and provide additional candidates for therapeutic up-regulation in DMD
by: Perkins, K, et al.
Published: (2012)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
by: Tinsley, J, et al.
Published: (2013)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
by: Janghra, N, et al.
Published: (2016)